- Poster presentation
- Open Access
Sex matters: retrospective data collection on the date of commencement of ART for HIV-positive women and men in the German KompNet cohort (1991-2009)
© Krznaric et al; licensee BioMed Central Ltd. 2010
Published: 8 November 2010
In Germany the majority of people living with HIV/AIDS are males and little is known about the characteristics and epidemiology of female HIV patients. The German KompNetKohort is a large, national retro- and prospective, multicenter, HIV-specific cohort, that documents HIV-positive patients since 1991. One important question we wanted to answer is in how much these two populations differ and whether a gender specific treatment approach is needed.
A thorough database analysis was conducted and male and female HIV patients of the German KompNetKohort were stratified for baseline characteristics, immunologic status (CD4+ counts, VL, opportunistic infections) before commencing ART, country of origin, way of transmission as well as the initial therapy regimen.
We analysed 3793 Patients (590 women (15.5%), 3203 men (84.4%)). The median age was 43,6 years for women and 47,64 for men. 137 female (23.3%) and 751 male (32.9%) had CD4- counts < 200 /µl, whereas 451 women and 1529 men showed CD4- counts > 200 CD4/µl ( p< 0.001). The initial therapy regimen was documented for 2216 patients. 215 women and 687 men started with a PI-based regimen, whereas 199 women were treated with an NNRTI and 1314 men ( p< 0.001). Other regimens where used 176 times in women and 1403 in men.
In the German KompNetCohort men had lower CD4-counts at the time of starting ART. Women were much more frequently treated with PI than men. A reason could be the restrictions in child bearing age for efavirenz and the CD4-cell count for nevirapine use.
It is not clear if the lower CD4-Cellcount at time of starting ART in men is due to late presentation. Further investigations are warranted.
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.